Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 912 participants.

Also called NCT01029886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 912 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01029886
Other papers using this trial's data
  • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet (London, England), 2013-01-12 DOI, PubMed 23141817

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01029886. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results posted on 2012-03-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
exenatide once weekly
Intervention (Drug)
liraglutide
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01029886
Content hash
11123d64bbb49df0f652fc6a9a1ec2d1d1a1147b8dc5019a3d9b30c56f03bd45